188 related articles for article (PubMed ID: 38332162)
1. Identification of potential inhibitor against Leishmania donovani mitochondrial DNA primase through in-silico and in vitro drug repurposing approaches.
Nath M; Bhowmik D; Saha S; Nandi R; Kumar D
Sci Rep; 2024 Feb; 14(1):3246. PubMed ID: 38332162
[TBL] [Abstract][Full Text] [Related]
2. Drug repurposing based novel anti-leishmanial drug screening using
Rai P; Arya H; Saha S; Kumar D; Bhatt TK
J Biomol Struct Dyn; 2022; 40(21):10812-10820. PubMed ID: 36529188
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of potential drugs against leishmaniasis targeting catalytic subunit of
Bhowmik D; Jagadeesan R; Rai P; Nandi R; Gugan K; Kumar D
J Biomol Struct Dyn; 2021 Mar; 39(5):1838-1852. PubMed ID: 32141397
[No Abstract] [Full Text] [Related]
4. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
Jain SK; Sahu R; Walker LA; Tekwani BL
J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
[TBL] [Abstract][Full Text] [Related]
5. Screening of Novel Inhibitors Against Leishmania donovani Calcium ion Channel to Fight Leishmaniasis.
Kashif M; Manna PP; Akhter Y; Alaidarous M; Rub A
Infect Disord Drug Targets; 2017; 17(2):120-129. PubMed ID: 28034363
[TBL] [Abstract][Full Text] [Related]
6. Repurposing Glyburide as Antileishmanial Agent to Fight Against Leishmaniasis.
Rub A; Shaker K; Kashif M; Arish M; Dukhyil AAB; Alshehri BM; Alaidarous MA; Banawas S; Amir K
Protein Pept Lett; 2019; 26(5):371-376. PubMed ID: 30827222
[TBL] [Abstract][Full Text] [Related]
7. Peptide-mediated leishmaniasis management strategy: Tachyplesin emerges as an effective anti-leishmanial peptide against Leishmania donovani.
Kumar V; Chugh A
Biochim Biophys Acta Biomembr; 2021 Aug; 1863(8):183629. PubMed ID: 33933430
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Leishmania donovani topoisomerase IB selective inhibitors by targeting protein-protein interactions between the large and small subunits.
Lee H; Baek KH; Phan TN; Park IS; Lee S; Kim J; No JH
Biochem Biophys Res Commun; 2021 Sep; 569():193-198. PubMed ID: 34256188
[TBL] [Abstract][Full Text] [Related]
9. Characterization of thiamine pyrophosphokinase of vitamin B1 biosynthetic pathway as a drug target of
Ranjan Kumar R; Jain R; Akhtar S; Parveen N; Ghosh A; Sharma V; Singh S
J Biomol Struct Dyn; 2024 Jul; 42(11):5669-5685. PubMed ID: 37350670
[TBL] [Abstract][Full Text] [Related]
10. Alkaloids and Leishmania donovani UDP-Galactopyarnosemutase: A Novel Approach in Drug Designing Against Visceral Leishmaniasis.
Srivastava A; Chandra D
Infect Disord Drug Targets; 2018; 18(2):145-155. PubMed ID: 28595543
[TBL] [Abstract][Full Text] [Related]
11. In silico screening, structure-activity relationship, and biologic evaluation of selective pteridine reductase inhibitors targeting visceral leishmaniasis.
Kaur J; Kumar P; Tyagi S; Pathak R; Batra S; Singh P; Singh N
Antimicrob Agents Chemother; 2011 Feb; 55(2):659-66. PubMed ID: 21115787
[TBL] [Abstract][Full Text] [Related]
12. Bestatin analogs-4-quinolinone hybrids as antileishmanial hits: Design, repurposing rational, synthesis, in vitro and in silico studies.
Hassan AHE; Mahmoud K; Phan TN; Shaldam MA; Lee CH; Kim YJ; Cho SB; Bayoumi WA; El-Sayed SM; Choi Y; Moon S; No JH; Lee YS
Eur J Med Chem; 2023 Mar; 250():115211. PubMed ID: 36827952
[TBL] [Abstract][Full Text] [Related]
13. Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach.
Pandey RK; Sharma D; Bhatt TK; Sundar S; Prajapati VK
J Biomol Struct Dyn; 2015; 33(12):2541-53. PubMed ID: 26305585
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani.
Zahid MSH; Johnson MM; Tokarski RJ; Satoskar AR; Fuchs JR; Bachelder EM; Ainslie KM
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():125-132. PubMed ID: 31493763
[TBL] [Abstract][Full Text] [Related]
15. The Effect of BTK Inhibitor Ibrutinib on Leishmania infantum Infection In Vitro.
Mert U; Müftüoğlu C; Erdem S; Sadıqova A; Toz S; Ozbel Y; Caner A
Acta Parasitol; 2022 Dec; 67(4):1732-1739. PubMed ID: 36260194
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of FDA-approved drugs as inhibitors of sterol C-24 methyltransferase of Leishmania donovani to fight against leishmaniasis.
Tabrez S; Rahman F; Ali R; Muhammad F; Alshehri BM; Alaidarous MA; Banawas S; Dukhyil AAB; Rub A
Drug Dev Res; 2021 Dec; 82(8):1154-1161. PubMed ID: 33929761
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani.
Kaur J; Sundar S; Singh N
J Antimicrob Chemother; 2010 Aug; 65(8):1742-8. PubMed ID: 20519355
[TBL] [Abstract][Full Text] [Related]
18. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
19. Genomic and Phenotypic Characterization of Experimentally Selected Resistant Leishmania donovani Reveals a Role for Dynamin-1-Like Protein in the Mechanism of Resistance to a Novel Antileishmanial Compound.
Hefnawy A; Negreira G; Jara M; Cotton JA; Maes I; D'Haenens E; Imamura H; Cuypers B; Monsieurs P; Mouchtoglou C; De Winter H; Pintelon I; Timmermans JP; Berriman M; Sanders M; Martin J; de Muylder G; Dujardin JC; Sterckx YG; Domagalska MA
mBio; 2022 Feb; 13(1):e0326421. PubMed ID: 35012338
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance.
Tandon R; Chandra S; Baharia RK; Das S; Misra P; Kumar A; Siddiqi MI; Sundar S; Dube A
Antimicrob Agents Chemother; 2014 Jun; 58(6):2997-3007. PubMed ID: 24614385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
